

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 25th day of August 2005.



By

Kelley D. Surprenant
(Signature of person mailing)
Kelley D. Surprenant

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Graham Nigel Maw and
Christopher Peter Wayman**

APPLICATION NO.: **09/939,093**

EXAMINER: **Leslie A. Royds**

FILED: **08/24/2001**

ART UNIT: **1614**

FOR: **Pharmaceutical**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

TERMINAL DISCLAIMER

Pfizer Inc., by its attorney of record, hereby declares that:

1. Pfizer Inc. is the assignee of all interest in the instant U.S. patent application and in co-pending U.S. Patent Application No. 10/017,273 ('273 Application).
2. Pfizer Inc. disclaims the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on the '273 Application. In making the above disclaimer, Pfizer Inc. does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 of any patent granted on the '273 Application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee.
5. Pfizer Inc. agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the '273 Application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

09939093

08/31/2005 HMRZ11 00000008 161445

01 FC:1614 130.00 DA

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

AUTHORIZATION OF PAYMENT

Authorization is hereby provided to charge the Terminal Disclaimer fee under 37 CFR 1.20(d) of \$130.00 and any additional fees due, or to credit any overpayments to Account Number 16-1445.

Date:

August 25, 2005

Respectfully submitted,



Gabriel Kleiman
Attorney for the Applicant(s)
Reg. No. 40,681

Pfizer Inc.
Patent Dept.
MS 8260-1611
Eastern Point Road
Groton, CT. 06340
(860) 715-0041